IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1301-1324 out of 1324.

<< < 48 | 49 | 50 | 51 | 52 | 53

Public Release: 27-Nov-2014
JAMA Otolaryngology - Head & Neck Surgery
Survival differences seen for advanced-stage laryngeal cancer
The five-year survival rate for advanced-stage laryngeal cancer was higher than national levels in a small study at a single academic center performing a high rate of surgical therapy, including a total laryngectomy, or removal of the voice box, to treat the disease, despite a national trend toward organ preservation, according to a report published online by JAMA Otolaryngology-Head & Neck Surgery.

Contact: Sally Croom
The JAMA Network Journals

Public Release: 27-Nov-2014
A numbers game: Math helps to predict how the body fights disease
Walter and Eliza Hall Institute researchers have defined for the first time how the size of the immune response is controlled, using mathematical models to predict how powerfully immune cells respond to infection and disease.
National Health and Medical Research Council, Human Frontier Science Program, Australian Research Council, Science Foundation Ireland, Australian Postgraduate Award scheme,Edith Moffatt Scholarship Fund, Victorian Government

Contact: Vanessa Solomon
Walter and Eliza Hall Institute

Public Release: 26-Nov-2014
56th American Society of Hematology Annual Meeting
New England Journal of Medicine
Two studies identify a detectable, pre-cancerous state in the blood
Researchers from the Broad Institute, Harvard Medical School, and Harvard-affiliated hospitals have uncovered an easily detectable, 'pre-malignant' state in the blood that significantly increases the likelihood that an individual will go on to develop blood cancers such as leukemia, lymphoma, or myelodysplastic syndrome. The discovery, which was made independently by two research teams affiliated with the Broad and partner institutions, opens new avenues for research aimed at early detection and prevention of blood cancer.
National Institutes of Health, Gabrielle's Angel Foundation, Leukemia and Lymphoma Society, Stanley Center for Psychiatric Research, NIH/National Human Genome Research Institute, NIH/National Institute of Mental Health, Wellcome Trust, and others

Contact: Veronica Meade-Kelly
Broad Institute of MIT and Harvard

Public Release: 26-Nov-2014
Study finds potential predictive biomarker for response to PD-L1 checkpoint blocker
Scientists analyzed tissue samples from patients who had -- and had not -- responded to a promising new immunotherapy drug. The study could help identify patients most likely to respond to the new drug, which blocks PD-L1.
Genentech Inc.

Contact: Teresa M Herbert
Dana-Farber Cancer Institute

Public Release: 26-Nov-2014
Cell Reports
Enzyme may be key to cancer progression in many tumors
A new University of Iowa study provided a deeper understanding of how KRAS turns off tumor suppressor genes and identifies a key enzyme in the process. The findings, published online Nov. 26 in the journal Cell Reports, suggest that this enzyme, known as TET1, may be an important target for cancer diagnostics and treatment.
NIH/National Cancer Institute

Contact: Jennifer Brown
University of Iowa Health Care

Public Release: 26-Nov-2014
Cancer Cell
Research on a rare cancer exposes possible route to new treatments
Researchers from Huntsman Cancer Institute at the University of Utah discovered the unusual role of lactate in the metabolism of alveolar soft part sarcoma and also confirmed that a fusion gene is the cancer-causing agent in this disease.
NIH/National Cancer Institute

Contact: Linda Aagard
University of Utah Health Sciences

Public Release: 26-Nov-2014
Scientists discover treatment breakthrough for advanced bladder cancer
Scientists from Queen Mary University of London have made a major breakthrough in developing a new therapy for advanced bladder cancer -- for which there have been no major treatment advances in the past 30 years.

Contact: Charli Scouller
Queen Mary, University of London

Public Release: 26-Nov-2014
How a common antacid could lead to cheaper anti-cancer drugs
A popular indigestion medication can increase survival in colorectal cancer, according to research published in ecancermedicalscience. But in fact, scientists have studied this for years -- and a group of cancer advocates want to know why this research isn't more widely used. 'Cimetidine is a drug that can meet patient needs now -- so we need to ask ourselves: what's stopping it being used?' asks Pantziarka.

Contact: Katie Foxall

Public Release: 26-Nov-2014
Critical Public Health
More public health interventions required to tackle grim reaper of 'lifestyle' diseases
More public health interventions, along the lines of the smoking ban, are needed to tackle Britain's devastating toll of 'lifestyle' diseases, including heart disease and cancer, according to academics.

Contact: Deborah Linton
University of Manchester

Public Release: 26-Nov-2014
Vaccines may make war on cancer personal
In the near future, physicians may treat some cancer patients with personalized vaccines that spur their immune systems to attack malignant tumors. New research led by scientists at Washington University School of Medicine in St. Louis has brought the approach one step closer to reality.

Contact: Michael C. Purdy
Washington University School of Medicine

Public Release: 26-Nov-2014
Study unlocks basis of key immune protein's two-faced role
A Brigham and Women's Hospital-led team has identified a long sought-after partner for a key immune protein, called TIM-3, that helps explain its two-faced role in the immune system.

Contact: Jessica Caragher
Brigham and Women's Hospital

Public Release: 26-Nov-2014
RSNA 2014 100th Scientific Assembly and Annual Meeting
Trial shows new imaging system may cut X-ray exposure for liver cancer patients
Johns Hopkins researchers report that their test of an interventional X-ray guidance device approved by the US Food and Drug Administration in 2013 has the potential to reduce the radiation exposure of patients undergoing intra-arterial therapy for liver cancer.
Max Kade Foundation, NIH/National Cancer Institute, Philips Research North America

Contact: Vanessa Wasta
Johns Hopkins Medicine

Public Release: 26-Nov-2014
SU2C-supported research discovers why patients respond to a life-saving melanoma drug
Reported in Nature online, Dr. Antoni Ribas, co-leader of the CRI-SU2C Immunology Dream Team and colleagues at UCLA Jonsson CCC studied tumor biopsies from 46 advance melanoma patients taken before and after treatment with pembrolizumab (Keytruda), the new FDA-approved breakthrough drug. Using biopsy findings created an algorithm to predict the likelihood whether patients would likely to respond to this treatment.
Stand Up To Cancer, National Institute of Health, UCLA Jonsson Comprehensive Cancer Center

Contact: Jane Rubinstein
Entertainment Industry Foundation

Public Release: 26-Nov-2014
Research team proves the efficacy of new drug against stem cells that provoke the growth of cancer
An Andalusian team of researchers led by the University of Granada has designed a drug that fights cancerogenic stem cells responsible for the onset and development of cancer, for relapse after chemotherapy, and for metastasis. The new drug, called Bozepinib, has been successfully tested in mice, and has a selective action against cancerogenic stem cells for breast and colon cancer, as well as melanoma.

Contact: Juan Antonio Marchal Corrales
University of Granada

Public Release: 25-Nov-2014
One-two punch of drugs better than either alone against colorectal cancer
Experimental anti-cancer agents PF-04691502 and PD-0325901 excel in lab tests against colorectal cancer models and enter phase 1 trial.
Pfizer, CU Cancer Center

Contact: Garth Sundem
University of Colorado Denver

Public Release: 25-Nov-2014
Researchers identify new ways to drain cancer's 'fuel tank'
Scientists at the University of Manchester have discovered a potential weakness in cancer's ability to return or become resistant to treatment, by targeting the 'fuel' part of stem cells which allows tumors to grow.
Breakthrough Breast Cancer and Cancer Research UK

Contact: Jamie Brown
University of Manchester

Public Release: 25-Nov-2014
Nature Communications
Why cancer cells grow despite a lack of oxygen
Healthy cells reduce their growth when there is a lack of oxygen (hypoxia). This makes it even more surprising that hypoxia is a characteristic feature of malignant tumors. In two publications in the current edition of the Nature Communications journal, researchers from Goethe University and the Justus-Liebig-University of Giessen report on how cancer cells succeed at circumventing the genetic program of growth inhibition.

Contact: Amparo Acker-Palmer
Goethe University Frankfurt

Public Release: 25-Nov-2014
Genetics in Medicine
Pathology specialist contributes to debate on breast cancer gene screening
What are the risks and benefits of screening for BRCA1 and BRCA2 mutations in the general adult population? Dr. Glenn Palomaki has published an invited commentary in Genetics in Medicine on this issue.

Contact: Amy Blustein
Care New England

Public Release: 25-Nov-2014
RSNA 2014 100th Scientific Assembly and Annual Meeting
New device may ease mammography discomfort
Researchers have developed a new device that may result in more comfortable mammography for women. According to a new study, standardizing the pressure applied in mammography would reduce pain associated with breast compression without sacrificing image quality.

Contact: Linda Brooks
Radiological Society of North America

Public Release: 25-Nov-2014
Science Signaling
New insights into breast cancer spread could yield better tests and treatments
A study combining patients' tumor cells with a laboratory model of blood vessel lining provides the most compelling evidence so far that a specific trio of cells is required for the spread of breast cancer. The findings could lead to better tests for predicting whether a woman's breast cancer will spread. The study, led by researchers at the NCI-designated Albert Einstein Cancer Center and Montefiore Einstein Center for Cancer Care, published today in Science Signaling.
National Institutes of Health, Breast Cancer Alliance, Department of Defense Breast Cancer Research Program, Einstein Integrated Imaging Program

Contact: Kim Newman
Albert Einstein College of Medicine

Public Release: 25-Nov-2014
Clinical Medicine Insights: Oncology
Therapy found effective in older, African-American lung cancer patients
University of Cincinnati researchers have found in a phase 2 clinical trial that a Food and Drug Administration-approved therapy could be effective in treating both older and African-American patients with advanced lung cancer who may not be candidates for chemotherapy.
Astra Zeneca

Contact: Katie Pence
University of Cincinnati Academic Health Center

Public Release: 25-Nov-2014
Proceedings of the National Academy of Sciences
Vegetable oil ingredient key to destroying gastric disease bacteria
The bacterium Helicobacter pylori is strongly associated with gastric ulcers and cancer. To combat the infection, researchers at University of California, San Diego School of Medicine and Jacobs School of Engineering developed LipoLLA, a therapeutic nanoparticle that contains linolenic acid, a component in vegetable oils. In mice, LipoLLA was safe and more effective against H. pylori infection than standard antibiotic treatments.
NIH/National Institute of Diabetes and Digestive and Kidney Diseases

Contact: Heather Buschman
University of California - San Diego

Public Release: 25-Nov-2014
Journal of Urology
Long-term testosterone therapy does not increase the risk of prostate cancer
Testosterone (T) therapy is routinely used in men with hypogonadism, a condition in which diminished function of the gonads occurs. Although there is no evidence that T therapy increases the risk of prostate cancer (PCa), there are still concerns and a paucity of long-term data. Investigators examined three parallel, prospective, ongoing, cumulative registry studies of over 1,000 men. Their analysis showed that long-term T therapy in hypogonadal men is safe and does not increase the risk of PCa.

Contact: Linda Gruner
Elsevier Health Sciences

Public Release: 25-Nov-2014
Proceedings of the National Academy of Sciences
A hybrid vehicle that delivers DNA
A new hybrid vehicle is under development. Its performance isn't measured by the distance it travels, but rather the delivery of its cargo: vaccines that contain genetically engineered DNA to fight HIV, cancer, influenza and other maladies. Described in the Proceedings of the National Academy of Sciences, the technology could help unleash the potential of DNA vaccines, which despite two decades of research, have yet to make a significant impact in the treatment of major illnesses.
National Institutes of Health

Contact: Cory Nealon
University at Buffalo

Showing releases 1301-1324 out of 1324.

<< < 48 | 49 | 50 | 51 | 52 | 53

  Search News Releases